Objective: Infants with transient tachypnea of the newborn (TTN) have relatively low levels of epinephrine, which is known to mediate fetal lung fluid absorption. Providing exogenous epinephrine could be a valuable diagnostic and therapeutic intervention for this common condition. Our primary objective was to determine if inhaled racemic epinephrine is safe for the treatment of TTN. Our secondary objective was to determine its efficacy.
Introduction
Transient tachypnea of the newborn (TTN) is a common condition in the full-term or late preterm infant 1, 2 with an estimated incidence of between 0.5 and 2.8% of all deliveries [2] [3] [4] [5] and between 1 and 30% of infants delivered by elective cesarean section. [6] [7] [8] [9] [10] [11] TTN results from delayed clearance of fetal lung fluid at birth 12, 13 and occurs in isolation or in association with other neonatal respiratory illnesses, such as surfactant deficiency, 14 neonatal pneumonia 14 and persistent pulmonary hypertension of the newborn. 15, 16 While TTN is a self-limiting condition, affected infants often undergo evaluation with laboratory testing, chest radiography and close monitoring in a special care nursery (SCN) or neonatal intensive care unit (NICU). Currently, treatment for TTN is supportive, including supplemental oxygen, withholding of enteral feeds and administration of intravenous fluids and antibiotics. 17 Rarely, infants require mechanical ventilation. 1, 18 Thus, despite its transient nature, TTN is a nontrivial cause of neonatal respiratory distress associated with a substantial use of health-care resources. 19 A therapy that is effective early in the course of illness would decrease treatment burden and resource utilization.
Potential therapies must be based on an understanding of the unique physiology of normal fetal lung fluid clearance at birth. Endogenous catecholamines assist the lung epithelium to transition, in the first few minutes after birth, from a secretory to an absorptive mode by inducing active sodium transport across the pulmonary epithelium. 12, 20, 21 Given the importance of catecholamines in enhancing absorption of fetal lung fluid, it is plausible that a relative catecholamine deficiency may play a role in the etiology of TTN, and that administration of exogenous catecholamines may be an effective treatment. Delivery by cesarean section, especially prior to the onset of labor, is associated with an increased risk of TTN. [7] [8] [9] [10] [11] [21] [22] [23] [24] Levels of circulating catecholamines are higher in newborns delivered vaginally than in newborns delivered by cesarean section, possibly due to the stimulation of catecholamine release by the stress of labor. 25 Catecholamine levels are lower in infants with TTN than in infants without TTN. 26 In a sheep model, infusion of epinephrine, a catecholamine hormone, decreased secretion and promoted the absorption of fetal lung fluid. [27] [28] [29] [30] Despite substantial evidence linking catecholamine hormones with TTN, no prior study in humans has examined the use of exogenous catecholamines for the treatment of TTN. Epinephrine is a catecholamine hormone available in systemic and inhaled form. Because of TTN's self-limiting and relatively mild symptoms, the risk of systemic epinephrine therapy is not warranted. Inhaled epinephrine, however, is theoretically ideal for reaching the lung while minimizing systemic effects. The only commercially available inhaled epinephrine is racemic epinephrine. It has a strong safety record for indications other than TTN, including postextubation stridor in neonates 31 and bronchiolitis in infants. 32 We conducted a randomized, blinded clinical trial of inhaled epinephrine for the treatment of TTN. We hypothesized that inhaled epinephrine would increase the rate of absorption of fetal lung fluid in newborns with TTN without causing adverse side effects. Our primary objective was to assess the safety of inhaled racemic epinephrine for this new indication. Our secondary objective was to test its efficacy.
Methods

Study population
We recruited infants from a community-based level II SCN and a level III NICU between 2001 and 2006. Patients were eligible for enrollment if they had completed X36 weeks of gestational age, were <6 h old at the time of enrollment and had TTN. TTN was defined as respiratory distress (grunting, flaring or retracting), supplemental oxygen requirement to maintain SpO 2 >95% and abnormal chest radiograph (fluid in minor fissure, hyperinflation, prominent vascular/perihilar markings).
Exclusion criteria were tachycardia (heart rate (HR) >180), arrhythmia, signs of persistent pulmonary hypertension (preductal SpO 2 saturation level X5% above postductal SpO 2 ), ventilatory support, suspected sepsis (perinatal risk factors, WBC <5000, immature-to-total neutrophil (I:T) ratio >0.25 or focal infiltrate on chest X-ray), suspected respiratory distress syndrome, cardiac or pulmonary congenital anomaly or exposure to maternal medications that could potentiate a subject's response to epinephrine.
Intervention
Written informed consent was obtained from the parents of all enrolled infants. Patients were randomized in a blinded manner to receive three doses of either nebulized 2 ml normal saline alone (placebo) or with 2.25% racemic epinephrine (Racepinephrine Inhalation Solution, USP, 2.25%. Nephron Pharmaceuticals, Orlando, FL, USA). The standard dose of racemic epinephrine is 0.05 ml kg À1 . 33 Treatment patients received a first dose of 0.025 ml kg À1 epinephrine, followed by two additional doses of 0.05 ml kg À1 . Each dose of the study drug was nebulized with 100% oxygen. The three doses were administered over the course of 30 min, and vital signs were monitored for a total of 2 h. The (blinded) study neonatologist monitored HR, respiratory rate (RR), pre-and postductal O 2 saturations, blood pressure (BP), fraction of inspired O 2 and the presence of grunting, flaring and retractions for 2 h from the initiation of the study drug. These variables were recorded at preseleted, discrete time points. Subsequent doses of epinephrine were discontinued if a patient experienced tachycardia, arrhythmia, systemic or persistent pulmonary hypertension. During and after the nebulized treatments, patients received care for TTN at the discretion of the medical team. Additional data were collected regarding time to room air, time of first enteral feed, time of discharge from the SCN/NICU, subsequent need for ventilatory support or antibiotic therapy and any adverse events that occurred during the hospitalization.
Outcomes
Our primary outcome was excessive tachycardia defined as HR >200. Our secondary outcomes related to safety were HR rise >20% above baseline, arrhythmias, systolic BP>85 mm Hg and preductal O 2 saturation X5% above postductal O 2 saturation. Our 
Sample size
The sample size of 20 subjects was designed to gather preliminary evidence about the effects of inhaled epinephrine on the cardiopulmonary status of newborn infants with TTN. We recognized that it was not feasible to enroll the number of patients that would be required to find rare adverse reactions. Given inhaled epinephrine's robust safety profile in newborns, we selected a 3:1 randomization plan to ensure that the preponderance of data was generated by the intervention group.
Statistical methods
The demographic characteristics of treatment and control groups were compared with t-tests and Fisher's exact tests. Change from baseline to each of the study intervals was computed for each patient for HR, RR and BP. Treatment and control groups' change from baseline was compared with t-tests at 30, 60 and 120 min. We created time-to-event curves of the treatment and control groups and used the log-rank test to compare them. Because of our small sample size, we did not conduct any subgroup or adjusted analyses. Data were analyzed using SAS version 9.1 and a P-value of <0.05 was considered statistically significant, except for the t-tests comparing the treatment and control groups at each of three times, when Bonferroni correction (P<0.017) was used to define statistical significance.
Ethics
The study was approved by the Institutional Review Boards at both participating hospitals. Our Data Safety Monitoring Board (DSMB) conducted an interim and final analysis and concluded that there was no indication for early termination and no study violations.
Results
We enrolled 20 subjects, of whom 15 were assigned to the treatment arm and 5 to the control arm. Nine subjects were recruited from the SCN and 11 subjects from the NICU. All enrolled patients completed the study. There was no significant demographic difference between our treatment and control groups with the exception of race; all of the babies who randomized to the control group were Caucasian. Ninety-five percent of the babies were delivered by cesarean section, 40% of whom were elective repeat sections. Seventy-five percent of the babies were male ( Table 1) .
None of the treatment patients experienced any of our outcomes pertaining to safety: tachycardia, arrhythmia or either systemic or pulmonary hypertension during the 2 -h study period. Regarding our primary outcome, there were no statistically significant differences in HR during study drug administration. At 30 min the treatment group had a 21-beats per minute higher mean HR compared with controls (P ¼ 0.07) (Figure 1 ).
Regarding our secondary safety outcomes, after completion of the administration of the study drug, three patients who had Inhaled epinephrine for TTN B Kao et al received epinephrine developed a rise in HR >20% above baseline that resolved by 60 min. The maximum rise in HR was 64% over baseline (from 118 to 194). The maximum absolute HR observed was 194 beats per minute. Although the systolic BP was similar between the two groups at all time points, at 30 min the diastolic BP was 11 mm Hg higher in the treatment group (P ¼ 0.0005) (Figure 1) . One patient in the treatment arm appeared to have a transient pre/postductal O 2 saturation differential of 5 points (100% preductal and 95% postductal) at time zero that had not been present at the time of enrollment, and resolved within minutes, such that by 5 min into the study period, the pre-and post-O 2 saturations were both 100%.
Regarding our secondary efficacy outcomes, the treatment group had a lower RR at each study time (Figure 2) . The difference in RR between groups at baseline was not statistically significant (t-test, P ¼ 0.13). At 60 min the mean RR of the treatment group was significantly lower than that of the control group (58 vs 77, P ¼ 0.011). However, the trend in normalization of RR was the same for the two groups (P>0.75). Times to room air, first feeding and discharge from SCN/NICU were not statistically different between groups (Figure 3 ). Clinical treatment with antibotics was also similar between the groups (treatment 73%, control 40%, P ¼ 0.29).
After the completion of the administration of the study drug, no patient received nebulized epinephrine during the remaining period of their hospitalization. Three patients, two treatment and one control, developed signs and symptoms consistent with surfactant deficiency. They all required mechanical ventilation. One additional treatment patient developed hypoglycemia requiring intravenous glucose therapy.
Discussion
In this pilot study of inhaled epinephrine for treatment of newborns with TTN, we did not identify any adverse events during treatment, specifically tachycardia, other arrhythmias, or either systemic or pulmonary hypertension. The transient rise in HR and diastolic BP noted at 30 min, as well as the three patients with a 
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Figure 3 Efficacy-related outcomes: time to room air, time to first feed and time to discharge from NICU.
Inhaled epinephrine for TTN B Kao et al >20% rise in HR above baseline after treatment all support a mild effect of systemic epinephrine absorption from the lung in our treatment group. This study did not have the power to detect rare adverse events. The two comorbid conditions we identified in our study were surfactant deficiency and hypoglycemia. On the basis of known effects of epinephrine on surfactant release 28, 34 and serum glucose levels, 35 these comorbid conditions are not attributable to the nebulized epinephrine.
Because epinephrine is a known systemic vasoconstrictor, this raised concerns about the possibility of it also causing pulmonary vasoconstriction, precipitating a spiral of persistent pulmonary hypertension. We monitored pre-and postductal O 2 saturations and did not observe any evidence of pulmonary hypertension in either our treatment or control patients.
Our study did not have sufficient statistical power to assess the efficacy of inhaled epinephrine for the treatment of TTN. The RR trend data must be interpreted in light of the fact that a less tachypneic group was randomly assigned to our treatment arm. That said, by 30 min the babies who received epinephrine had a mean RR <70 (mean 67, s.d. 16), generally the cutoff for offering oral feedings. By contrast, the control group still had a mean RR of >80 (mean 83, s.d. 24) at the end of the 2 h observation period. An intervention that decreased the RR to <70 within 2 h of intervention would be an improvement over the condition of our controls.
Because by definition TTN resolves spontaneously, administration of inhaled epinephrine for diagnostic and/or treatment purposes would need to have both a marked and a relatively prompt effect. Feasibility of providing this potential therapy in any newborn nursery setting would depend on the availability of appropriate monitoring equipment and a health-care provider trained to administer inhaled therapies to newborns. This is the first clinical trial studying the role of inhaled epinephrine for the treatment of TTN. We found no adverse events when inhaled epinephrine was administered to newly born, full-term babies with moderate-to-severe TTN. A larger study is necessary to determine the efficacy of inhaled epinephrine as a diagnostic and therapeutic intervention for this common respiratory condition.
